<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">DANNER, BERNHARD C.</style></author><author><style face="normal" font="default" size="100%">DIDILIS, VASSILIOS N.</style></author><author><style face="normal" font="default" size="100%">WIEMEYER, STEFAN</style></author><author><style face="normal" font="default" size="100%">STOJANOVIC, TOMISLAV</style></author><author><style face="normal" font="default" size="100%">KITZ, JULIA</style></author><author><style face="normal" font="default" size="100%">EMMERT, ALEXANDER</style></author><author><style face="normal" font="default" size="100%">FÜZESI, LASZLO</style></author><author><style face="normal" font="default" size="100%">SCHÖNDUBE, FRIEDRICH A.</style></author></authors><secondary-authors></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Long-term Survival Is Linked to Serum LDH and Partly to Tumour LDH-5 in NSCLC</style></title><secondary-title><style face="normal" font="default" size="100%">Anticancer Research</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2010</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2010-04-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">1347-1351</style></pages><volume><style face="normal" font="default" size="100%">30</style></volume><issue><style face="normal" font="default" size="100%">4</style></issue><abstract><style  face="normal" font="default" size="100%">Background: Lactate formation is up-regulated in tumorous cells by lactate dehydrogenase (LDH). High serum LDH level is linked to many malignancies with poorer survival, but tumour LDH-5 has not been well investigated in non-small cell lung cancer (NSCLC). Patients and Methods: In 89 patients operated on for NSCLC stage I-III, the serum LDH level was assayed and immunohistochemistry for tumour LDH-5 was performed. Impact on long-term survival and correlation was analysed. Results: High serum LDH was associated with poorer survival (p&lt;0.001). No correlation was revealed between serum LDH and the tumour LDH-5. Only in tumours greater than 3 cm were high tumour LDH-5 values associated with higher serum LDH values (p=0.04) and in this subgroup, high tumor LDH-5 was associated with poorer long-term survival (p=0.024). Conclusion: High serum LDH has a negative impact on long-term survival in NSCLC, whereas for tumour LDH-5, this was seen only in a subgroup of patients with larger tumours. Copyright© 2010 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved</style></abstract></record></records></xml>